Castle biosciences stock.

Castle Biosciences is a commercial-stage diagnostics company that provides testing services for dermatological cancers. …CASTLE BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 77-0701774 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.) ... registrant’s common stock on June 30, 2020, as reported by the Nasdaq Global Market. As of March 5, 2021, there were 24,978,424 shares of …How much is Castle Biosciences stock worth today? ( NASDAQ: CSTL) Castle Biosciences currently has 26,910,548 outstanding shares. With Castle Biosciences …Castle Biosciences Inc (CSTL) Stock Price & News - Google Finance Markets 34,932.41 -0.037% 4,509.11 +0.019% +0.87 14,101.58 -0.086% -12.09 1,795.29 +21.54 VIX 13.72 …

Castle Biosciences had a GAAP loss of 70 cents a share, approximately 20 cents a share above expectations. Revenues rose 44% on a year-to-year basis to $50.1 million, almost $6 million over the ...Stock analysis for Castle Biosciences Inc (CSTL:NASDAQ GM) including stock price, stock chart, company news, key statistics, fundamentals and company profile.

Castle Biosciences Inc Stock Price History. Castle Biosciences Inc’s price is currently down 22.91% so far this month. During the month of October, Castle Biosciences Inc’s stock price has reached a high of $16.84 and a low of $12.07. Over the last year, Castle Biosciences Inc has hit prices as high as $29.59 and as low as $9.26. Year to ...

Castle Biosciences Inc’s trailing 12-month revenue is $192.0 million with a -39.3% profit margin. Year-over-year quarterly sales growth most recently was 66.2%. Analysts expect adjusted earnings to reach $-2.723 per share for the current fiscal year. Castle Biosciences Inc does not currently pay a dividend.Materials used to build castles include earth, wood and stone. Motte-and-bailey castles were made of earth and wood, but due to weaknesses in these castles, stone castles were created.Best Stock Of The Week Castle Biosciences Cstl Option Informants Based on 3 Wall Street analysts offering 12 month price targets for Castle Biosciences in the last 3 months. . 1 day agoSVB Securities analyst Puneet Souda maintained a Buy rating on Castle Biosciences CSTL - Research Report on November 2 and set a price target of …Castle Biosciences, Inc. (NASDAQ:CSTL) Q3 2023 Earnings Call Transcript. Castle Biosciences, Inc. (NASDAQ:CSTL) Q3 2023 Earnings Call Transcript November 3, 2023 Operator: Good afternoon and welcome to Castle Biosciences Third Quarter 2023 Conference Call. As a reminder, today’s call is being recorded.

52.55K (21.02% of Avg) 65 Day Avg: 250.03K Becton Dickinson & Co. Siemens Healthineers AG Qiagen N.V. Company & People Research & Ratings President, Chief Executive Officer & Director Franklin...

Castle Biosciences Market Cap: 537.40M, Enterprise value: 484.98M, P/E: -8.76, PEG ratio: 0.08, EPS: -2.84, Revenue: 192.00M, EBITDA: -64.35M, ...

Castle Biosciences stock gains ~9% after co reports beat-and-raise Q2 SA News Tue, Aug. 09, 2022 1 Comment. Castle Biosciences GAAP EPS of -$0.06 beats by $0.70, revenue of $34.8M beats by $6.43MThe estimated Net Worth of Mara G. Aspinall is at least 2.53 百万$ dollars as of 25 August 2022. Ms. Aspinall owns over 6,000 units of Castle Biosciences stock worth over 1,731,228$ and over the last 8 years she sold CSTL stock worth over 494,800$. In addition, she makes 302,714$ as Independent Director at Castle Biosciences.Contact Information. Customer Service: 866-788-9007 Option 1 [email protected]. Reimbursement: 866-788-9007 Option 3 [email protected] hares of Castle Biosciences (NASDAQ: CSTL) were down more than 47% on Monday afternoon as three analysts lowered their price targets for the medical diagnostic stock. The healthcare stock is ...Castle Biosciences had a GAAP loss of 70 cents a share, approximately 20 cents a share above expectations. Revenues rose 44% on a year-to-year basis to $50.1 million, almost $6 million over the ...Understanding stock price lookup is a basic yet essential requirement for any serious investor. Whether you are investing for the long term or making short-term trades, stock price data gives you an idea what is going on in the markets.Key Insights Significantly high institutional ownership implies Castle Biosciences' stock price is sensitive to their...

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Castle Biosciences with a $34.00 average price target, implying a 67.49% upside from current levels.Forecst.com predicts future values using technical analysis of a large number of analytical parameters. CSTL stock returns are also predicted based on historical data. According to our research, CSTL stock is a bad long-term investment. CSTL share price has been in a bear cycle for the past year. Castle Biosciences, Inc. stock trend is …Nov 11, 2021 · The stock price of Castle Biosciences (NASDAQ: CSTL), a skin cancer diagnostic company, has seen a fall of over 9% last month, while it is down 12% in a week. The recent fall can be attributed to ... Castle Biosciences Stock Forecast 11-20-2023. Forecast target price for 11-20-2023: $ 18.23. Negative dynamics for Castle Biosciences shares will prevail with possible volatility of 2.962%. Pessimistic target level: 17.92. Optimistic target level: 18.47.Investing in the stock market takes a lot of courage, a lot of research, and a lot of wisdom. One of the most important steps is understanding how a stock has performed in the past. Of course, the past is not a guarantee of future performan...

Jul 11, 2023 · Castle Biosciences makes tests for patients diagnosed with certain diseases to help evaluate optimal treatment options. Read my analysis of CSTL stock here. ... Castle stock had fallen to ~$33 per ...

Castle Biosciences, Inc. is a commercial-stage diagnostics company. The Company is focused on providing physicians and their patients with personalized, clinically actionable information to clinicians and their patients to inform treatment decisions and improve health outcomes.... stock price multiplied by the number of shares outstanding. Castle Biosciences net worth as of November 17, 2023 is $0.53B. Compare CSTL With Other Stocks ...The estimated net worth of David S. Kabakoff is at least $3.83 million as of June 22nd, 2020. Mr. Kabakoff owns 212,178 shares of Castle Biosciences stock worth more than $3,831,935 as of November 6th. This net worth evaluation does not reflect any other investments that Mr. Kabakoff may own. Learn More about David S. Kabakoff's net …KMO: Director of Operations - Castle Biosciences; Stock Ownership - Castle Biosciences. PJLS: Other Remuneration - Indiana University. SB: Other Remuneration - Indiana University. This does not alter the authors' adherence to all the PLOS ONE policies on sharing data and materials. Introduction. Thymomas and thymic …Key Insights. Significantly high institutional ownership implies Castle Biosciences' stock price is sensitive to their trading actions. 51% of the business is held by the top 12 shareholdersJun 5, 2023 · Castle Biosciences Inc (CSTL) stock is down -47.58% while the S&P 500 has gained 0.08% as of 10:52 AM on Monday, Jun 5. CSTL is lower by -$10.81 from the previous closing price of $22.73 on volume of 2,678,434 shares. Over the past year the S&P 500 is up 3.99% while CSTL is lower by -44.69%. CSTL lost -$2.71 per share the over the last 12 months.

Castle Biosciences, Inc. is a commercial-stage dermatological cancer company, which engages in the provision of genomic information for physicians and patients. The company offers DecisionDx-Melanoma, a proprietary multi-gene expression profile (GEP) test that predicts the risk of metastasis and recurrence for patients diagnosed with invasive ...

Nov 24, 2023

Jun 5, 2023 · According to 7 analyst offering 12-month price targets in the last 3 months, Castle Biosciences has an average price target of $35.14 with a high of $41.00 and a low of $25.00. The bid-ask spread can indicate a stock’s liquidity, which is how easy it is to buy and sell in the marketplace. Often, a smaller spread suggests higher liquidity, meaning more buyers …Castle Biosciences is the only provider of 31-GEP testing, and all testing is performed in a College of American Pathologists/Clinical Laboratory Improvement Amendments–certified laboratory. We evaluated the ability of the 31-GEP to stratify risk in MSS and overall survival (OS) to confirm the prognostic ability of the 31-GEP at the …Castle Biosciences Company Info. Castle Biosciences, Inc. is a commercial-stage dermatological cancer company, which engages in the provision of genomic information for physicians and patients. Nov 17, 2023 · 4 Wall Street research analysts have issued 1-year price targets for Castle Biosciences' shares. Their CSTL share price targets range from $25.00 to $41.00. On average, they anticipate the company's stock price to reach $32.29 in the next twelve months. This suggests a possible upside of 64.4% from the stock's current price. The estimated Net Worth of Kristen M Oelschlager is at least $2.3 Million dollars as of 28 December 2022. Ms. Oelschlager owns over 7,178 units of Castle Biosciences stock worth over $1,593,448 and over the last 2 years she sold CSTL stock worth over $710,200. In addition, she makes $0 as Senior Vice President - Clinical …Castle Biosciences, Inc. (CSTL) came out with a quarterly loss of $0.78 per share versus the Zacks Consensus Estimate of a loss of $0.91. This compares to loss of $0.25 per share a year ago.See the latest Castle Biosciences Inc stock price (CSTL:XNAS), related news, valuation, dividends and more to help you make your investing decisions.Overview. Castle Biosciences is improving health through our innovative tests that guide patient care. For the diseases that our portfolio of tests cover, we believe the traditional approach to developing a treatment plan for cancers and other diseases using clinical and pathology factors alone is inadequate and can be improved by incorporating …In a report released on July 7, Puneet Souda from SVB Securities maintained a Buy rating on Castle Biosciences (CSTL – Research Report).The company’s shares closed last Friday at $20.30 ...Insiders trading at Castle Biosciences. Over the last 4 years, insiders at Castle Biosciences have traded over $369,408,068 worth of Castle Biosciences stock and bought 782,652 units worth $12,524,690 . The most active insiders traders include Daniel Bradbury, Derek J Maetzold, and Joseph C. Iii Cook.On average, Castle …

See the latest Castle Biosciences Inc stock price (CSTL:XNAS), related news, valuation, dividends and more to help you make your investing decisions.Key Insights. Significantly high institutional ownership implies Castle Biosciences' stock price is sensitive to their trading actions. 51% of the business is held by the top 12 shareholdersCastle Biosciences, Inc. (CSTL) came out with a quarterly loss of $0.77 per share versus the Zacks Consensus Estimate of a loss of $0.70. This compares to loss of $0.47 per share a year ago.Instagram:https://instagram. brics forexqualcomm dividendlost tribewhy nvidia stock is down today The latest Castle Biosciences stock prices, stock quotes, news, and CSTL history to help you invest and trade smarter. stock price cgcbest futures to day trade The stock price of Castle Biosciences, a skin cancer diagnostic company, has seen a large 24% drop over the last ten trading days, while it is down 14% over the last five trading days.Europe PMC is an archive of life sciences journal literature. daytradedash Nov 24, 2023 · Castle Biosciences Inc CSTL Morningstar Rating Stock XNAS Rating as of Nov 24, 2023 Summary Chart News Price vs Fair Value Sustainability Trailing Returns Financials Valuation Operating... Revenue growth over the past 12 months for CASTLE BIOSCIENCES INC comes in at 55.17%, a number that bests 91.18% of the US stocks we're tracking. Stocks with similar financial metrics, market capitalization, and price volatility to CASTLE BIOSCIENCES INC are SILK, ONTF, IGC, FLGT, and BMRA. Visit CSTL's SEC page to see the company's …Europe PMC is an archive of life sciences journal literature. https://orcid.org